Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma Services AG
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine
The primary objective is to determine the target dose of canakinumab for the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine. The target do...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106
To evaluate the safety and tolerability of repeated subcutaneous (s.c.) injections of 150µg CAD106 in patients with mild Alzheimer's Disease over the 52 weeks of the study.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An exploratory haemodynamic study in patients with compensated cirrhosis and portal hypertension
The main purpose of this exploratory study is to investigate the effect of serelaxin (RLX030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertensi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with moderate to severe atopic dermatitis
EASI50 response, defined as a decrease in Eczema Area and Severity Index (EASI) of at least 50% compared to baseline
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease
To assess the long-term safety and tolerability of AIN457 in patients with moderate to severe Crohn’s disease who participated in the core CAIN457A2202 phase II proof-of-concept study
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate
Efficacy of AIN457 at 16 weeks on ACR20 response.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A phase IA/II, two-arm, multi-center, open-label, dose-escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies
1. MTD and DLT of single agent LBH589B when administered orally, once-a-day on MWF, every week, in adult patients with advanced hematologic malignancies which has progressed despite standard therapy o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 device
To assess the bronchodilator effect of once-daily indacaterol as a PulmoSphereTM formulation and lactose-blended indacaterol in adult patients with persistent asthma compared with placebo as measured ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Six-month open label extension to an efficacy and safety study of Ritalin LA in the treatment of adult patients with childhood-onset ADHD
•To evaluate the long-term safety of Ritalin LA administered once daily for six months during open-label treatment in adults with ADHD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A multi-center study to assess the safety, effectiveness and tolerance of a study drug FTY720 in patients with certain types of the eye disease uveitis (inflammation in the back of the eye)
To assess the effect of FTY720 on vitreous haze at Day 8 in patients with acute noninfectious posterior, intermediate, or pan uveitis
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
10
11
12
13
14
15
16
17
18
19
Next